002432 九安医疗
2023/06 - 中期
人民幣(K¥)
与去年同期
比较
2022/12
人民幣(K¥)
2021/12
人民幣(K¥)
2020/12
人民幣(K¥)
2019/12
人民幣(K¥)
营业总收入2,282,753-90.19%26,315,3612,397,0982,008,360706,276
减:营业总成本1,261,196-77.03%7,434,7301,447,6841,572,994870,103
    其中:营业成本771,437-82.43%5,367,195875,549877,505502,937
               财务费用(179,221)277.17%(209,149)2,60218,7841,106
               资产减值损失(331,543)27,140.90%(321,559)(9,274)(177,698)(112,638)
公允价值变动收益172,645-874.05%(326,401)30,489(335,946)305,968
投资收益216,965-18,516.25%93,48345,583317,5411,491
    其中:对联营企业和合营企业的投资收益----(1,266)(1,380)(332)(89)
营业利润1,093,713-93.84%18,311,8691,002,549238,58820,536
利润总额1,095,019-93.83%18,257,857999,632239,75318,382
减:所得税费用140,089-90.20%1,773,76365,2292,925(8,678)
净利润954,930-94.15%16,484,094934,403236,82827,060
减:非控股权益169,114-84.15%453,92525,761(5,501)(39,390)
股东净利润785,816-94.84%16,030,169908,642242,32966,449

市场价值指针
每股收益 (元) *1.669-95.01%35.1381.9990.5600.150
每股派息 (元) *----2.5000.7000.060--
每股净资产 (元) *41.1907.73%40.3575.9674.3553.841
审计意见 #--标准的无保留意见标准的无保留意见标准的无保留意见标准的无保留意见
回页顶
备注: *未调整数据
#只提供简体内容